top of page

NVIDIA Generative AI:  Drug Discovery and Design

NVIDIA BioNeMo, which is fueling the computer-aided drug discovery ecosystem, now features more than a dozen generative AI models and cloud services.

In perhaps the healthcare industry’s most dramatic transformation since the advent of computing, digital biology and generative AI are helping to reinvent drug discovery, surgery, medical imaging and wearable devices.

NVIDIA Generative AI Is Opening the Next Era of Drug Discovery and Design NVIDIA BioNeMo, which is fueling the computer-aided drug discovery ecosystem, now features more than a dozen generative AI models and cloud services. January 8, 2024 by Kimberly Powell Share In perhaps the healthcare industry’s most dramatic transformation since the advent of computing, digital biology and generative AI are helping to reinvent drug discovery, surgery, medical imaging and wearable devices. NVIDIA has been preparing for this moment for over a decade, building deep domain expertise, creating the NVIDIA Clara healthcare-specific computing platform and expanding its work with a rich ecosystem of partners. Healthcare customers and partners already consume well over a billion dollars in NVIDIA GPU computing each year — directly and indirectly through cloud partners.

In the $250 billion field of drug discovery, these efforts are meeting an inflection point: R&D teams can now represent drugs inside a computer. By harnessing emerging generative AI tools, drug discovery teams observe foundational building blocks of molecular sequence, structure, function and meaning — allowing them to generate or design novel molecules likely to possess desired properties. With these capabilities, researchers can curate a more precise field of drug candidates to investigate, reducing the need for expensive, time-consuming physical experiments.

Accelerating this shift is NVIDIA BioNeMo, a generative AI platform that provides services to develop, customize and deploy foundation models for drug discovery.

Aktuelle Beiträge

Alle ansehen

Kommentare


bottom of page